BRGX — BioRegenx Cashflow Statement
0.000.00%
- $12.51m
- $14.71m
- $2.34m
Annual cashflow statement for BioRegenx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.085 | -0.262 | -0.117 | -3.6 | -23.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.023 | 0.165 | 0.039 | 2.5 | 20 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.038 | -0.027 | 0.008 | -0.422 | 0.531 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.094 | -0.12 | -0.065 | -1.52 | -0.324 |
| Capital Expenditures | — | — | — | -0.049 | -0.189 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | 0 | -0.15 | 0.001 |
| Acquisition of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | — | 0 | -0.199 | -0.188 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.15 | 0.05 | 0.041 | 1.2 | 0.442 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.056 | -0.07 | -0.024 | -0.491 | -0.067 |